Metabolic Syndrome in Patients With Diabetes Mellitus

Essafi, Mohammed Amine; bouabdellaoui, Latifa; Aynaou, Hayat; Salhi, H.; Ouahabi, H. El

doi:10.7759/cureus.24469

Cited by 6 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, glucose control, blood pressure and body composition represent key clinical indicators of future diabetes complications. 27 In contrast to SCORE-IT, 25 we also included diabetes distress. This reflects the need to account for the relationship between mental and physical health in interventions for type 2 diabetes in people who have co-existing SMI.…”

Section: Discussionmentioning

confidence: 99%

“…We needed to ensure that the number of outcomes was manageable and would not be burdensome to measure and that they would be relevant across all trials evaluating self‐management of people with type 2 diabetes and co‐existing SMI, including trials focused on people who are newly diagnosed with type 2 diabetes. However, glucose control, blood pressure and body composition represent key clinical indicators of future diabetes complications 27 . In contrast to SCORE‐IT, 25 we also included diabetes distress.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A core outcome set for trials evaluating self‐management interventions in people with severe mental illness and coexisting type 2 diabetes

Carswell,

Taylor,

Holt

et al. 2024

Diabet Med

View full text Add to dashboard Cite

BackgroundPeople with severe mental illness (SMI), such as schizophrenia, have higher rates of type 2 diabetes and worse outcomes, compared to those without SMI and it is not known whether diabetes self‐management interventions are effective for people who have both conditions. Research in this area has been impeded by a lack of consensus on which outcomes to prioritise in people with co‐existing SMI and diabetes.AimsTo develop a core outcome set (COS) for use in effectiveness trials of diabetes self‐management interventions in adults with both type 2 diabetes and SMI.MethodsThe COS was developed in three stages: (i) identification of outcomes from systematic literature review of intervention studies, followed by multi‐stakeholder and service user workshops; (ii) rating of outcomes in a two‐round online Delphi survey; (iii) agreement of final ‘core’ outcomes through a stakeholder consensus workshop.ResultsSeven outcomes were selected: glucose control, blood pressure, body composition (body weight, BMI, body fat), health‐related quality of life, diabetes self‐management, diabetes‐related distress and medication adherence.ConclusionsThis COS is recommended for future trials of effectiveness of diabetes self‐management interventions for people with SMI and type 2 diabetes. Its use will ensure trials capture important outcomes and reduce heterogeneity so findings can be readily synthesised to inform practice and policy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A core outcome set for trials evaluating self‐management interventions in people with severe mental illness and coexisting type 2 diabetes

Carswell,

Taylor,

Holt

et al. 2024

Diabet Med

View full text Add to dashboard Cite

show abstract

“…Furthermore, the predictive value of meeting metabolic syndrome criteria for cardiovascular risk and events may differ in patients with or without diabetes. However, in patients with T2D, metabolic syndrome has shown to predict atherosclerosis, is an independent predictor of cardiovascular disease, is an indicator of microvascular and macrovascular complications and increased risk of adverse cardio-renal outcomes [ 58 – 61 ]. Moreover, the present post hoc analysis did not include separate thresholds for waist circumference in Asians.…”

Section: Discussionmentioning

confidence: 99%

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program

Nicholls,

Tofé,

le Roux

et al. 2024

Cardiovasc Diabetol

View full text Add to dashboard Cite

Background Metabolic syndrome is characterized as the co-occurrence of interrelated cardiovascular risk factors, including insulin resistance, hyperinsulinemia, abdominal obesity, dyslipidemia and hypertension. Once weekly tirzepatide is approved in the US and EU for the treatment of type 2 diabetes (T2D) and obesity. In the SURPASS clinical trial program for T2D, tirzepatide demonstrated greater improvements in glycemic control, body weight reduction and other cardiometabolic risk factors versus placebo, subcutaneous semaglutide 1 mg, insulin degludec, and insulin glargine. This post hoc analysis assessed the effect of tirzepatide use on the prevalence of patients meeting the criteria for metabolic syndrome across SURPASS 1–5. Methods Metabolic syndrome was defined as having ≥ 3 of 5 criteria according to the US National Cholesterol Education Program: Adult Treatment Panel III. Analyses were based on on-treatment data at the primary endpoint from patients adherent to treatment (taking ≥ 75% study drug). A logistic regression model with metabolic syndrome status as the response variable, metabolic syndrome status at the baseline visit as an adjustment, and randomized treatment as fixed explanatory effect was used. The effect of tirzepatide use on the prevalence of patients meeting the criteria for metabolic syndrome by categorical weight loss, background medication and gender were assessed. Results In SURPASS, the prevalence of patients meeting the criteria for metabolic syndrome at baseline was 67–88% across treatment groups with reductions at the primary endpoint to 38–64% with tirzepatide versus 64–82% with comparators. Reductions in the prevalence of patients meeting the criteria for metabolic syndrome was significantly greater with all tirzepatide doses versus placebo, semaglutide 1 mg, insulin glargine, and insulin degludec (p < 0.001). Individual components of metabolic syndrome were also reduced to a greater extent with tirzepatide vs comparators. Greater reductions in body weight were associated with greater reductions in the prevalence of patients meeting the criteria for metabolic syndrome and its individual components. Background SGLT2i or sulfonylurea use or gender did not impact the change in prevalence of patients meeting the criteria for metabolic syndrome. Conclusions In this post hoc analysis, tirzepatide at all doses studied was associated with a greater reduction in the prevalence of patients meeting the criteria for metabolic syndrome compared to placebo, semaglutide 1 mg, insulin degludec, and insulin glargine. Although more evidence is needed, these data would support greater potential improvement in cardiovascular risk factor profile with tirzepatide treatment in people across the continuum of T2D.

show abstract

“…This is attributed to the fact that both type 2 diabetes and metabolic syndrome have the same pathophysiology of insulin resistance, and more severe insulin resistance is associated with a higher prevalence of metabolic syndrome [ 33 ]. However, metabolic syndrome in patients with type 2 diabetes is significantly associated with macro-vascular and micro-vascular complications, including decreased renal function [ 34 , 35 , 36 ], and, in particular, is highly correlated with decreased renal function in middle-aged people (adults in their 40s and 50s [ 37 ]. Therefore, healthcare professionals need to pay attention to the high prevalence of metabolic syndrome in this population.…”

Section: Discussionmentioning

confidence: 99%

Analysis of the Association between Metabolic Syndrome and Renal Function in Middle-Aged Patients with Diabetes

Park

Lee

2022

IJERPH

View full text Add to dashboard Cite

This study investigated the effects of metabolic syndrome on the estimated glomerular filtration rate in middle-aged participants with diabetes to provide basic data to enable the development of education programs for middle-aged people to prevent diabetic kidney disease. This cross-sectional descriptive study analyzed data obtained in the 2nd year of the 8th Korea National Health and Nutrition Examination Survey in 2020 and enrolled 279 participants aged 40–65 years who were diagnosed with diabetes. Multilevel stratified cluster sampling was used to improve the representativeness of the samples and the accuracy of parameter estimation. The risk factors of metabolic syndrome and the risk of elevated eGFR were analyzed using regression analysis and the correlation between the variables was determined using Pearson’s correlation analysis. Middle-aged participants with diabetes whose eGFR was <90 showed a significant difference in their risk for metabolic syndrome based on sex, age, disease duration, and total cholesterol concentrations. Systolic blood pressure and waist circumference in men, and waist circumference and HDL cholesterol level in women were identified as risk factors that contribute to the increasing prevalence of metabolic syndrome.

show abstract

Metabolic Syndrome in Patients With Diabetes Mellitus

Cited by 6 publications

References 29 publications

A core outcome set for trials evaluating self‐management interventions in people with severe mental illness and coexisting type 2 diabetes

A core outcome set for trials evaluating self‐management interventions in people with severe mental illness and coexisting type 2 diabetes

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program

Analysis of the Association between Metabolic Syndrome and Renal Function in Middle-Aged Patients with Diabetes

Contact Info

Product

Resources

About